Anti-Platelet Drug Provides Superior Protection Of Acute Coronary Syndromes

Armen Hareyan's picture
Advertisement

Acute Coronary Syndromes

Advertisement

A new landmark study by the Brigham and Women's Hospital-based TIMI Study Group has found the new anti-platelet drug prasugrel to be superior to clopidogrel in more rapidly and consistently preventing serious events among study participants undergoing coronary stent procedures. The findings were presented at the American Heart Association's Scientific Sessions 2007 in Orlando, FL and are available in a fast-track on-line publication of the New England Journal of Medicine.

The TIMI Study Group conducted the phase 3 clinical trial TRITON-TIMI 38 and enrolled 13,608 patients with moderate to high-risk acute coronary syndromes (ACS), such as unstable angina or heart attack, who were scheduled to undergo percutaneous coronary intervention (PCI, receiving a coronary stent to open a blocked artery).

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement